Compass pathways stock forecast.

Currently 16 wall-street analysts regularly analyze the financials of Compass Pathways Plc on a frequent basis to provide recommendations along with target share price. 16 analysts offering 12-month price forecasts for Compass Pathways Plc (CMPS) have a share price target of $42.13.Web

Compass pathways stock forecast. Things To Know About Compass pathways stock forecast.

COMPASS Pathways ’s (CMPS) stock price is $6.1 and COMPASS Pathways ’s (CMPS) 200-day simple moving average is 8.13, creating a Sell signal. COMPASS Pathways (CMPS) Technical Indicators Dec 02, 2023, 11:33 AMCOMPASS Pathways PLC (CMPS) stock is down -1.77% while the S&P 500 is higher by 1.89% as of 2:59 PM on Thursday, Apr 27. CMPS has fallen -$0.15 from the previous closing price of $8.17 on volume of 236,713 shares. Over the past year the S&P 500 has fallen -1.22% while CMPS has fallen -21.27%. CMPS lost -$0.01 per share the …Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ...WebA high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Web

A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Compass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ...2 พ.ย. 2566 ... Stock FTCH logo. FTCH · Farfetch Will Not Announce Third Quarter 2023 ... price prior to the financing, and will be exercisable at the election ...

COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ...WebCOMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors. Transaction led by healthcare specialist investors, TCGX and Aisling Capital. Net ...Web1 de jul. de 2023 ... While Compass Pathways' (CMPS 2.17%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by ...Compass IPO'd in September 2020, raising $147m at $17 per share, so the stock is only trading at a 35%-40% discount to its listing price, which is not too bad based on current biotech bear market ...Shares of the Peter Thiel -backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling ...

The COMPASS Pathways plc stock forecast for tomorrow is $ 5.02, which would represent a -4.68% loss compared to the current price. In the next week, the price of CMPS is expected to decrease by -2.62% and hit $ 5.13. As far as the long-term COMPASS Pathways plc stock forecast is concerned, here’s what our predictions are currently suggesting.

A. While ratings are subjective and will change, the latest Compass Pathways ( CMPS) rating was a reiterated with a price target of $0.00 to $21.00. The current price Compass Pathways ( CMPS) is ...

The consensus 12-month price target for Compass Pathways reflects an upside potential of close to 325%. Even the most pessimistic analyst surveyed by Refinitiv thinks that the stock will double ...WebApr 20, 2023 · With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ... Find the latest analyst research for COMPASS Pathways Plc American Depository Shares (CMPS) at Nasdaq.com.WebZacks forecast a loss of 55 cents per share. The company had zero revenue, as its main product, COMP360, is still in trials. ... Compass Pathways stock is in an IPO base with a 47.39 buy point.69.32%. Get the latest Compass Pathways PLC (CMPS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.From this work, Compass Pathways in my opinion is trading at around its current market price. Figure 6: Valuation of Compass Pathways (Source: Author's valuation work, using base data from CMPS' 10-K)

CMPS : Long term COMPASS Pathways plc stock forecast for 2022, 2023 (1 year) - 2025 - 2027 (5 year) - 2030, and 2032 (10 year). Forecast for 2024 Jan. is $6.19 ...Nov 11, 2021 · Compass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ... Stock Price Forecast The 11 analysts offering 12-month price forecasts for Doximity Inc have a median target of 25.00, with a high estimate of 31.00 and a low estimate of 21.00.What is the current Price Target and Forecast for COMPASS Pathways (CMPS) COMPASS Pathways (CMPS) (Real Time Quote from BATS) $5.93 USD +0.10 …Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...WebDescription. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways …A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Web

Market Activity. Funds + ETFs. Analyst ratings can be used in addition to other personal research work prior to making investment decisions. Do Not Sell My Personal Information (CA Residents Only ...

CMPS. COMPASS Pathways plc. 5.83. -0.22. -3.64%. COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to ...COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary.Compass shares are also dragging in late 2023, down 26.3% on a year-to-date basis. The U.K.-based biotech, which specializes in psilocybin research for treating depression, recently landed $285 ...CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings data on November 2nd, 2023. The reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted …WebCurrent price today: 6.450 USD (+1.896%) History Forecast Data Market Q&A Comments Buy CRYPTO Select other stock... Current Price 6.450 USD 7 Days Forecast Get It …Biotechnology firm COMPASS Pathways (CMPS) Wednesday announced a private placement of 16.08M American Depositary Shares and warrants to purchase up to 16.08M ADSs at a price of $7.78...Get Compass Pathways PLC (CMPS.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.Still, Compass Pathways stock sank 16% in the stock market today. That's after tumbling 12% on Monday from an eight-month high. Compass also reported financial results for the third quarter.10 stocks we like better than Compass Pathways Plc When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor ...First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 . Compass Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in …

Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target....CMPS Compass Pathways (CMPS) has grabbed the interest of Canaccord Genuity analyst Sumant Kulkarni, who gave the biotech company an $80 price target....

Asset Growth. -34.43%. Trailing 12-Months. The COMPASS Pathways Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system …

In September of 2020, at $17 per share, Compass Pathways stock completed its public offering. Since the initial offering, CMPS has traded as high as $60 per share and seems to average out in the ...Based on short-term price targets offered by six analysts, the average price target for COMPASS Pathways PLC Sponsored ADR comes to $48.67. The forecasts range from a low of $19.00 to a high...Compass IPO'd in September 2020, raising $147m at $17 per share, so the stock is only trading at a 35%-40% discount to its listing price, which is not too bad based on current biotech bear market ...On average, Wall Street analysts predict. that Compass Pathways's share price could reach $57.25 by Aug 22, 2024. The average Compass Pathways stock price prediction forecasts a potential upside of 857.36% from the current CMPS share price of $5.98. That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51%).COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary.CMPS - Compass Pathways Plc - ADR Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)(Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ...Web

COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Atai bought another 619,095 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%. The new shares were bought at around $31 each, meaning Atai paid around $12 ...2 พ.ย. 2566 ... Each share of common stock and accompanying common warrant to purchase one share of common stock are being sold at a combined price to the ...Instagram:https://instagram. jandj snack foodsggb stocksbest dental plan in californiawhat is a good platform for day trading COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).Despite the potential of EVgo, Inc. (EVGO), Amyris, Inc. (AMRS), and COMPASS Pathways plc (CMPS) springing a surprise during the earnings season, their less-than-ideal fundamentals deem it wise to avoid placing any long-term bets on these heavily shorted stocks.In 2021, easy money, unprecedented hype created by retail … can you paper trade crypto on webullhow to purchase walmart stock What this means: InvestorsObserver gives Compass Pathways Plc ADR (CMPS) an overall rank of 34, which is below average. Compass Pathways Plc ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system. mvst news Shares of Compass Pathways (CMPS 6.61%) have soared since the company's recent stock market debut as support grows for the use of popular recreational drugs to combat depression.Key Points. Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices. Wall Street analysts have ...